UCB Korea said its dual inhibitor targeting interleukin-17A and 17F, Bimzelx (ingredient: bimekizumab), has been approved by the Ministry of Food and Drug Safety (MFDS) for the treatment of moderate-to-severe plaque psoriasis in adults who require phototherapy or systemic therapy. According to UCB, Bimzelx is the first and only treatment for plaque psoriasis that simultaneously inhibits IL-17A and IL-17F, cytokines that play a central role in the inflammatory process associated with psoriasis. ....
Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate-to-severe plaque psoriasis in adults, receives health insurance benefits in Korea for treating adult patients with chr...
Bimzelx is an injectable medicine. Here’s how it treats moderate to severe plaque psoriasis.
Chronic plaque psoriasis, also known as psoriasis vulgaris (chronic stationary type). Plaque psoriasis is a common, chronic and inflammatory skin disorder.
Compare risks and benefits of common medications used for Plaque Psoriasis. Find the most popular drugs, view ratings and user reviews.
Psoriasis usually presents with symmetrical, scaly plaques with well-defined edges. Factors that can trigger psoriasis include smoking, obesity, medications such as some anti-inflammatories and lit...
Plaque psoriasis is an autoimmune condition that can affect your skin, including your scalp. Prescription and over-the-counter medications can reduce symptoms.
Taltz is a monoclonal antibody. Here’s how it treats plaque psoriasis.
Psoriasis is an immune-mediated chronic inflammatory condition affecting the skin, joints, and other systems of the body. Plaque psoriasis is the most common type of psoriasis in which inflamed ery...
Topicals are a common medication for plaque psoriasis. Here’s what to expect, including what type to use, side effects, and how long to use them.